Neil Hunn
President and Chief Executive Officer at Roper Technologies
Thanks, Rob. Let's turn to Page 12, and walk through our Application Software segment. Revenues in this segment were $603 million, up 10% on an organic basis. EBITDA margins were 44.4% in the quarter. Across the segment, we saw organic recurring revenue, which is a touch north of 75% of the revenue for this segment increased approximately 10%. This recurring revenue strength is based on strong customer retention, continued migration to our SaaS delivery models, cross-selling activity and new customer adds. Across this group of companies, the financial strength was broad.
To highlight a few businesses Deltek our enterprise software business that serves the US federal contractor, architect, engineering, and other services end markets had another good quarter. During the quarter demand was particularly strong and enterprise GovCon and construction end markets. Importantly during the quarter Deltek also had success at the top in the market with their cloud or SaaS solutions.
Vertafore our agency management cloud software business focused on P&C insurance agencies also had a nice quarter with very strong new bookings and nice expansion activity in some of their largest customers. Aderant our legal software business continued its momentum and market share gains. As we talked about last quarter Aderant is gaining momentum for their SaaS solutions this quarter setting a record for SaaS bookings activity.
Consistent with the theme of this segment PowerPlan was strong as well, both in terms of new bookings and ads to the recurring revenue base, it's nice to see PowerPlan's refocused strategy start to pay dividends. As it relates to our health care IT businesses, Strata, Data Innovations and CliniSys were rock solid in the quarter. For Strata their recurring subscription-based software solutions continue to perform well and grew nicely. Strata's integration of EPSi is on track and nearly complete. The customer base continues to demonstrate excitement for this combination. Finally CliniSys continues to gain market share in the UK lab market and has been established as one of the four strategic IT partners for the NHS.
As we turn to the outlook for the fourth quarter, we expect organic recurring -- excuse me, we expect organic revenue growth to be similar to that of the third quarter as recurring revenue growth rates are expected to remain strong. A solid quarter here for sure.
And with that let's turn to the next slide. Turning to Page 13, the financial performance for this segment, as well the next to MAS and PT are shown on a continuing ops basis. Revenues in our network segment were $343 million, up 17% on organic basis, and EBITDA margins remained very strong at 51.6% in the quarter. The software businesses and this segment are now greater than 90% of the segment's revenue. Our NSS software growth was broad-based and driven by organic recurring revenue growth of approximately 17%.
At the business level, our Freight Match businesses, both in the US and Canada continue to be solid growers. As a reminder, our Freight Match networks are critical and necessary helmets to help organize and transact the trucking, shipping, spot markets. Strength in our businesses have been on both sides of the network brokers and carriers with continued strength in the quarter on the carrier side of the network. In addition, these businesses had improving revenue per customer ARPU as a value of the network continues to increase with higher levels of network activity.
Foundry our Media and Entertainment Software business, which enables the combination of live-action and computer generated graphics to be combined into a single frame demonstrated continued recovery and growth in the quarter. Worth pointing out as Foundry's continued commitment the product innovation and the recent release of their AI-enabled Nuke features that allow for more automated workflow steps within the video compositing process.
Our businesses that focus in and around the US long-term care markets MHA, SHP and SoftWriters did particularly well in the quarter. iTradeNetwork our perishable food supply chain network business had a nice quarter as bookings growth was very strong and demonstrate this followed recovery in their end markets.
Finally, we saw growth across the two product businesses within this segment, RF IDeas and Inovonics with particular strength and our Health Care end markets. As we look to the fourth quarter outlook, we expect to see low double-digit growth in this segment, again on a continuing ops basis.
Please turn to the next slide. As we turn to Page 14 revenue in our MAS segment were $392 million, up 9% on organic basis. Organic growth in this segment excluding Verathon was again north of 20%. Notably, this is the last quarter for the very difficult Verathon COVID comp and we expect Verathon's return to growth in Q4. EBITDA margins for this segment were 32.4% in the quarter. The EBITDA margins in this segment were consistent with our expectations, but lower than prior year, due to Verathon's extraordinary prior-year quarter and the cost impacts of certain businesses is navigating their supply chain challenges. Again, these results are on a continuing ops basis.
Before getting into business specific details across this segment demand can be characterized as being very strong. The demand was across all businesses and across both capital and consumable products. Product backlogs are up over 50%, as compared to a year ago. Our businesses, each of which were impacted by supply chain challenges navigated through the quarter. As it relates to individual business performance Verathon coming off unprecedented demand for their intubation family of products a year ago is roughly 40% larger today versus 2019. The momentum within this business continues given the larger installed base of intubation capital equipment, which enables recurring consumable pull through volumes.
In addition Verathon is experiencing impressive growth when their Bronchoscope product family and sustained growth across their bladder scan ultrasound franchise. Our other medical product businesses accelerated nicely in the quarter, with particular strength that NDI and CIVCO medical solutions.
Strong demand at Neptune continued in the quarter. Neptune's end markets continue to open up and improved, but have not fully recovered, especially in the Northeast US and Canada. Demand across our industrial business was robust as well and performance was strong, but somewhat impacted by supply chain challenges. For the fourth quarter we expect low double-digit organic growth for this segment. This is based on continued encouraging market conditions both in medical and industrial markets and easing prior year comps for Verathon.
Now let's turn to our final segment Process Tech. As we turn to Page 15, revenues in our Process Tech segment were $124 million, up 16% on organic basis. EBITDA margins were 31.6% in the quarter. These results are also reported on a continuing ops basis. The short story here is we're seeing improving end market conditions across virtually every one of our businesses in this segment and strong demand both orders and backlog were up approximately 50% in the quarter versus a year ago. Recovery in our upstream oil and gas businesses accelerated in the quarter. Cornell continues to perform well for us. This is particularly pass excuse me this is partially based on market conditions, but also based on Cornell's product innovation as they're seeing very nice demand pickup for their IoT connected pumping solutions.
Similar to that of our MAS industrial businesses, the businesses in this segment are being impacted by supply chain challenges, but continue to navigate through these issues. As we turn to the outlook for the fourth quarter, we expect high-teens organic growth based on improving market conditions.
Now please turn to Page 17, where I'll highlight our increased outlook for 2021. Based on strong year-to-date performance and expected continued momentum we're establishing full-year 2021 guidance on a continuing ops basis, a $14.08 to $14.12. As you read on this table you will note that the full-year DEPS impact for the businesses being divested is $1.18. If you combine this with our newly established continuing ops guidance you will note, we are raising our full-year outlook on an apples-to-apples basis by $0.26 in the low-end and $0.10 on the high end. As it relates to the fourth quarter, we're establishing again on a continuing ops basis guidance in the range of $3.62 and $3.66.
Now let's turn to our summary and get to your questions. As we turn to Page 18 and our closing summary, our third quarter was a solid quarter from both an operational and financial perspective. Simultaneously, we undertook significant work to further the transformation of our business portfolio. Revenue, EBITDA and DEPS grew 20% plus, organic revenue was up 12%. Across our enterprise end market and customer demand was strong in terms of software, product capital items and consumables. Throughout the quarter, our product businesses navigated through the market based supply chain challenges. Given all of this, we're able to increase on an apples-to-apples basis, our outlook for the full-year.
We also continue to deleverage our balance sheet by $1.8 billion since the 2020 acquisitions with net leverage now coming in at 3.5 times trailing EBITDA. As it relates to the strategic governance of our enterprise we're excited to be announcing the addition of Irene and Tom as new members of our Board of Directors. As part of our long-term Board refreshment strategy these two new Directors will complement our existing Directors and help enable Roper to continue our track record of long-term cash flow compounding.
Over the last decade, we have worked to enhance the quality of our portfolio. To this end, recently we took actions to meaningfully improve the quality of our portfolio by agreeing to divest TransCore, Zetec and CIVCO Radiotherapy. Once complete Roper will be a better version of Roper. We'll have higher proportion of recurring revenue, higher organic growth prospects and be significantly more asset light.
In addition, we expect to have roughly $5 billion of capital available to deploy between now and the end of 2022. And as it relates to our M&A pipeline it is and always has been characterized as having many high-quality opportunities. So we're clear, we are 100% back on offense when it comes to our capital deployment portion of our strategy and have fully resumed our usual process oriented and disciplined M&A activities.
And with that, let's open up to your questions.